Skip to main content
Passa alla visualizzazione normale.

ALICE TURDO

Role of Type I and II interferons in colorectal cancer and melanoma

  • Authors: Franco, S.; Turdo, A.; Todaro, M.; Stassi, G.
  • Publication year: 2017
  • Type: Recensione in rivista (Recensione in rivista)
  • Key words: Anti-cancer therapy; Cancer; Cancer progression; Colon; Interferon; Melanoma; Tumor immunology; Immunology and Allergy; Immunology
  • OA Link: http://hdl.handle.net/10447/245916

Abstract

Cancer can be considered an aberrant organ with a hierarchical composition of different cell populations. The tumor microenvironment, including the immune cells and related cytokines, is crucial during all the steps of tumor development. In particular, type I and II interferons (IFNs) are involved in a plethora of mechanisms that regulate immune responses in cancer, thus balancing immune escape versus immune surveillance. IFNs are involved in both the direct and indirect regulation of cancer cell proliferation and metastatic potential. The mutational background of genes involved in IFNs signaling could serve as a prognostic biomarker and a powerful tool to screen cancer patients eligible for checkpoint blocking therapies. We herewith describe the latest findings regarding the contribution of IFNs in colorectal cancer and melanoma by researching their dual role as either tumor promoter or suppressor, in diverse tumor types, and microenvironmental context. We are reporting the most innovative and promising approaches of IFN-based therapies that have achieved considerable outcomes in clinical oncology practice and explain the possible mechanisms responsible for their failure.